Promising Phase News Today

HealthFLD, a fully automated AI software for liver attenuation analysis from CT scans, has received FDA 510(k) clearance for use in the general population.

Stephen Harrison, MD, provides insight into the use of resmetirom for NASH with fibrosis ahead of the thyroid hormone receptor-β selective agonist’s March 14 PDUFA date.

Protagonist Therapeutics Inc (NASDAQ:PTGX) announced topline results from the Phase 2b FRONTIER 1 trial of the oral interleukin-23 receptor (...

Results also presented during late-breaking session at ESC Heart Failure congress 2023 ZURICH, SWITZERLAND, May 22, 2023 - (ACN Newswire) - Neurimmune announced today that primary results of its Phase 1 proof-of-concept study of NI006, a recombinant ...

Neurimmune: Promising Phase 1 Results for Antibody NI006 in ATTR Cardiomyopathy ...

Results also presented during late-breaking session at ESC Heart Failure congress 2023 ZURICH, May 20, 2023 (Newswire.com) - Neurimmune announced today that primary results of its Phase 1 proof-of-concept stud...

The scheme is intended to generate green jobs and attract private investment.